August 19, 2021
Otsuka Pharmaceutical said on August 18 that it has received Japanese regulatory approval for OD tablet versions of its antipsychotic agent Rexulti (brexpiprazole). The approval was granted on August 17 for 0.5 mg, 1 mg, and 2 mg OD tablets...read more